Sandwich, United Kingdom

Patrick Stephen Johnson



 

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 59(Granted Patents)


Location History:

  • Sandwich, Kent, GB (2010)
  • Sandwich, GB (2006 - 2014)

Company Filing History:


Years Active: 2006-2014

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Patrick Stephen Johnson: Innovator in Pharmaceutical Compounds

Introduction

Patrick Stephen Johnson is a notable inventor based in Sandwich, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific proteins involved in various diseases. With a total of 10 patents to his name, Johnson's work has the potential to impact the treatment of serious health conditions.

Latest Patents

Among his latest patents, Johnson has developed alkoxy-substituted 2-aminopyridines as ALK inhibitors. This invention relates to compounds of Formula (1) and outlines processes for their preparation, intermediates used in their synthesis, and the therapeutic uses of these derivatives. The compounds are particularly useful in treating diseases where ALK protein plays a critical role, especially in cancers mediated by a mutated EML4-ALK fusion protein. Additionally, he has patented compounds useful in therapy, which provide pharmaceutical compositions for treating disorders indicated by V1a antagonists, notably dysmenorrhoea.

Career Highlights

Throughout his career, Johnson has worked with prominent organizations, including Pfizer Corporation. His experience in the pharmaceutical industry has allowed him to develop innovative solutions that address pressing medical needs.

Collaborations

Johnson has collaborated with notable colleagues such as Justin Stephen Bryans and Thomas Ryckmans. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Patrick Stephen Johnson's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through targeted therapies. His work continues to pave the way for advancements in the treatment of diseases linked to ALK proteins and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…